

Carrie L Langstraat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2089352/publications.pdf>

Version: 2024-02-01

39
papers

1,043
citations

516710

16
h-index

434195

31
g-index

39
all docs

39
docs citations

39
times ranked

1379
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall survival after surgical staging by lymph node dissection versus sentinel lymph node biopsy in endometrial cancer: a national cancer database study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 28-40.	2.5	7
2	Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100923.	0.6	6
3	Surgical Scienceâ€™Symbionix Robotic Hysterectomy Simulator: Validating a New Tool. <i>Journal of Minimally Invasive Gynecology</i> , 2022, 29, 759-766.	0.6	1
4	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 475-483.	4.7	45
5	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 460-474.	4.7	67
6	Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy. <i>Gynecologic Oncology</i> , 2021, 160, 681-687.	1.4	13
7	The shift from inpatient to outpatient hysterectomy for endometrial cancer in the United States: trends, enabling factors, cost, and safety. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 686-693.	2.5	9
8	Image-guided tumor ablation in gynecologic oncology: Review of interventional oncology techniques and case examples highlighting a collaborative, multidisciplinary program. <i>Gynecologic Oncology</i> , 2021, 160, 835-843.	1.4	5
9	Sequencing chemotherapy before radiotherapy for women with stage IIIC endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 702-708.	2.5	6
10	Advanced ovarian cancer patients identify opportunities for prehabilitation: A qualitative study. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100731.	0.6	9
11	Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2594-2604.	1.6	66
12	Comparing survival outcomes between surgical and radiographic lymph node assessment in locally advanced cervical cancer: A propensity score-matched analysis. <i>Gynecologic Oncology</i> , 2020, 156, 320-327.	1.4	15
13	Implementing robotic surgery for uterine cancer in the United States: Better outcomes without increased costs. <i>Gynecologic Oncology</i> , 2020, 156, 451-458.	1.4	27
14	Management and outcomes of primary vaginal Cancer. <i>Gynecologic Oncology</i> , 2020, 159, 456-463.	1.4	27
15	Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. <i>Gynecologic Oncology</i> , 2020, 159, 434-441.	1.4	16
16	Survival outcomes in patients with cervical cancer treated with open versus robotic radical hysterectomy: Our surgical pathology interrogation. <i>Gynecologic Oncology</i> , 2020, 159, 373-380.	1.4	15
17	A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100574.	0.6	26
18	External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 797-805.	2.5	11

#	ARTICLE	IF	CITATIONS
19	Provider Knowledge and Support of Uterus Transplantation: Surveying Multidisciplinary Team Members. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 150-158.	2.4	5
20	Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 646-652.	1.4	16
21	Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management. <i>Gynecologic Oncology</i> , 2020, 157, 572-577.	1.4	19
22	Impact of Sentinel Node Approach in Gynecologic Cancer on Training Needs. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 727-732.	0.6	6
23	Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 58-62.	1.4	31
24	Review of the Outcomes of Ovarian Cancer Treated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy. <i>Indian Journal of Gynecologic Oncology</i> , 2019, 17, 1.	0.3	0
25	Paraneoplastic nodular regenerative hyperplasia of the liver associated with placental site trophoblastic tumor. <i>Gynecologic Oncology Reports</i> , 2019, 29, 16-19.	0.6	3
26	Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 286-292.	1.4	26
27	Enhanced Recovery after Minimally Invasive Gynecologic Procedures with Bowel Surgery: A Systematic Review. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 288-298.	0.6	28
28	Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 223-227.	1.4	17
29	Using quality improvement to increase the awareness of obesity among endometrial cancer patients. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1010-1015.	2.5	5
30	Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy. <i>Gynecologic Oncology</i> , 2018, 149, 291-296.	1.4	12
31	Frozen Section for Detection of Lymph Nodes After Cervical Injection with Indocyanine Green (ICG) for Sentinel Lymph Node Technique in Endometrial Cancer Staging. <i>Annals of Surgical Oncology</i> , 2018, 25, 3692-3698.	1.5	17
32	Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. <i>Gynecologic Oncology</i> , 2017, 145, 21-26.	1.4	58
33	Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia<sup />. <i>Journal of Women's Health</i> , 2017, 26, 368-373.	3.3	15
34	Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. <i>Gynecologic Oncology</i> , 2017, 144, 266-273.	1.4	38
35	Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses. <i>Gynecologic Oncology</i> , 2017, 147, 514-520.	1.4	6
36	Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 104-109.	1.4	92

#	ARTICLE	IF	CITATIONS
37	Using Bundled Interventions to Reduce Surgical Site Infection After Major Gynecologic Cancer Surgery. <i>Obstetrics and Gynecology</i> , 2016, 127, 1135-1144.	2.4	95
38	Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 311-316.	1.4	103
39	Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 140, 15-21.	1.4	80